Jacqueline Czwojdak
Medical · Horseheads, NYNPI 1285186320
Payments from drug & device makers
Across 371 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$892
- Amgen$631
- Takeda Pharmaceuticals U.S.A., Inc.$574
- Grifols USA, LLC$500
- Regeneron Healthcare Solutions, Inc.$433
- plus $2K from 18 others
What the payments were for
- Food & beverage$6,55099%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 73 | $1,533 |
| GSK | 79 | $892 |
| Amgen(2 entities) | 33 | $631 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $574 |
| Grifols USA, LLC | 30 | $500 |
| Regeneron Healthcare Solutions, Inc. | 27 | $433 |
| Pfizer | 22 | $429 |
| Sanofi | 19 | $360 |
| CSL Behring | 12 | $265 |
| Optinose US, Inc. | 16 | $237 |
| Novartis | 8 | $201 |
| Biocryst US Sales Co., LLC | 6 | $128 |
| Boehringer Ingelheim | 6 | $100 |
| Pharming Healthcare, Inc. | 3 | $69 |
| Genentech USA, Inc. | 3 | $67 |
| Merck | 2 | $31 |
| Alk-abello, Inc | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Incyte Corporation | 1 | $18 |
| Octapharma USA, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,584 in reported general payments places this provider in the 90th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 16 | $56,179 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $48,010 |
| EucrisaCrisaborole | 13 | $21,541 |
| Spiriva RespimatTiotropium Bromide | 18 | $12,970 |
| DuleraMometasone/Formoterol | 22 | $8,649 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $8,215 |
| QnaslBeclomethasone Dipropionate | 18 | $6,508 |
| Desloratadine | 110 | $4,627 |
| Arnuity ElliptaFluticasone Furoate | 16 | $4,517 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $3,633 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $3,342 |
| Mometasone Furoate | 32 | $2,720 |
| Epinephrine | 14 | $2,277 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,256 |
| Ipratropium Bromide | 32 | $2,123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $892 | $60,74189 claims |
| PfizerEucrisa | $429 | $21,54113 claims |
| Boehringer IngelheimSpiriva Respimat | $100 | $12,97018 claims |
| MerckDulera | $31 | $8,64922 claims |
| Teva Pharmaceuticals USA, Inc.Qnasl | $14 | $6,50818 claims |
| AstraZenecaSymbicort | $1,533 | $3,63312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,395 medical providers in New York.
Other medical in Horseheads
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
- Hailey BrickmanNew York$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.